A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Inclusion Criteria

• •1. Male or female participants 18 years or older, with relapsed or refractory classical Hodgkin lymphoma (HL), who have previously received at least 1 prior systemic chemotherapeutic regimen
• •2. Not suitable for stem cell transplantation (SCT) or multiagent chemotherapy, according to 1 of the following criteria:
• •* Disease progression within 90 days of the earliest date of complete remission (CR) or complete remission unconfirmed (CRu) after the end of treatment with multiagent chemotherapeutic regimens and/or radiotherapy
• •* Progressive disease during frontline multiagent chemotherapy
• •* Disease relapse after treatment with at least 2 chemotherapeutic regimens, including any salvage treatments
• •3. Bidimensional measurable disease
• •4. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
• •5. Female participants who are postmenopausal for at least 1 year before the screening visit, surgically sterile, or agree to practice 2 effective methods of contraception at the same time, or agree to practice true abstinence.
• •6. Male participants who agree to practice effective barrier contraception during the entire study treatment period through 6 months after the last dose of study drug or agree to practice true abstinence.
• •7. Clinical laboratory values as specified in the study protocol.